These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
364 related articles for article (PubMed ID: 1450944)
1. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study. Good PF; Olanow CW; Perl DP Brain Res; 1992 Oct; 593(2):343-6. PubMed ID: 1450944 [TBL] [Abstract][Full Text] [Related]
2. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. Hirsch EC; Brandel JP; Galle P; Javoy-Agid F; Agid Y J Neurochem; 1991 Feb; 56(2):446-51. PubMed ID: 1988548 [TBL] [Abstract][Full Text] [Related]
3. Elemental mapping of Neuromelanin organelles of human Substantia Nigra: correlative ultrastructural and chemical analysis by analytical transmission electron microscopy and nano-secondary ion mass spectrometry. Biesemeier A; Eibl O; Eswara S; Audinot JN; Wirtz T; Pezzoli G; Zucca FA; Zecca L; Schraermeyer U J Neurochem; 2016 Jul; 138(2):339-53. PubMed ID: 27121280 [TBL] [Abstract][Full Text] [Related]
4. Magnetic resonance correlation of iron content with neuromelanin in the substantia nigra of early-stage Parkinson's disease. Reimão S; Ferreira S; Nunes RG; Pita Lobo P; Neutel D; Abreu D; Gonçalves N; Campos J; Ferreira JJ Eur J Neurol; 2016 Feb; 23(2):368-74. PubMed ID: 26518135 [TBL] [Abstract][Full Text] [Related]
5. XANES spectroscopy of a single neuron from a patient with Parkinson's disease. Yoshida S; Ektessabi A; Fujisawa S J Synchrotron Radiat; 2001 Mar; 8(Pt 2):998-1000. PubMed ID: 11513007 [TBL] [Abstract][Full Text] [Related]
6. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease. Sasaki M; Shibata E; Tohyama K; Takahashi J; Otsuka K; Tsuchiya K; Takahashi S; Ehara S; Terayama Y; Sakai A Neuroreport; 2006 Jul; 17(11):1215-8. PubMed ID: 16837857 [TBL] [Abstract][Full Text] [Related]
7. Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease. Faucheux BA; Martin ME; Beaumont C; Hauw JJ; Agid Y; Hirsch EC J Neurochem; 2003 Sep; 86(5):1142-8. PubMed ID: 12911622 [TBL] [Abstract][Full Text] [Related]
8. In vivo detection of iron and neuromelanin by transcranial sonography--a new approach for early detection of substantia nigra damage. Berg D J Neural Transm (Vienna); 2006 Jun; 113(6):775-80. PubMed ID: 16755382 [TBL] [Abstract][Full Text] [Related]
9. Nanoscale synchrotron x-ray analysis of intranuclear iron in melanised neurons of Parkinson's substantia nigra. Brooks J; Everett J; Hill E; Billimoria K; Morris CM; Sadler PJ; Telling N; Collingwood JF Commun Biol; 2024 Aug; 7(1):1024. PubMed ID: 39164395 [TBL] [Abstract][Full Text] [Related]
10. The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease. Biondetti E; Santin MD; Valabrègue R; Mangone G; Gaurav R; Pyatigorskaya N; Hutchison M; Yahia-Cherif L; Villain N; Habert MO; Arnulf I; Leu-Semenescu S; Dodet P; Vila M; Corvol JC; Vidailhet M; Lehéricy S Brain; 2021 Nov; 144(10):3114-3125. PubMed ID: 33978742 [TBL] [Abstract][Full Text] [Related]
11. Correlation between pathology and neuromelanin MR imaging in Parkinson's disease and dementia with Lewy bodies. Kitao S; Matsusue E; Fujii S; Miyoshi F; Kaminou T; Kato S; Ito H; Ogawa T Neuroradiology; 2013 Aug; 55(8):947-953. PubMed ID: 23673875 [TBL] [Abstract][Full Text] [Related]
12. Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease. Zecca L; Casella L; Albertini A; Bellei C; Zucca FA; Engelen M; Zadlo A; Szewczyk G; Zareba M; Sarna T J Neurochem; 2008 Aug; 106(4):1866-75. PubMed ID: 18624918 [TBL] [Abstract][Full Text] [Related]
13. The enigma of neuromelanin in Parkinson's disease substantia nigra. Youdim MB; Ben-Shachar D; Riederer P J Neural Transm Suppl; 1994; 43():113-22. PubMed ID: 7884393 [TBL] [Abstract][Full Text] [Related]
14. Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis. Jellinger K; Kienzl E; Rumpelmair G; Riederer P; Stachelberger H; Ben-Shachar D; Youdim MB J Neurochem; 1992 Sep; 59(3):1168-71. PubMed ID: 1494904 [TBL] [Abstract][Full Text] [Related]
15. Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour. Zecca L; Tampellini D; Gerlach M; Riederer P; Fariello RG; Sulzer D Mol Pathol; 2001 Dec; 54(6):414-8. PubMed ID: 11724917 [TBL] [Abstract][Full Text] [Related]
16. Reproducible detection of nigral iron deposition in 2 Parkinson's disease cohorts. Langley J; He N; Huddleston DE; Chen S; Yan F; Crosson B; Factor S; Hu X Mov Disord; 2019 Mar; 34(3):416-419. PubMed ID: 30597635 [TBL] [Abstract][Full Text] [Related]
17. Interaction of neuromelanin and iron in substantia nigra and other areas of human brain. Zecca L; Shima T; Stroppolo A; Goj C; Battiston GA; Gerbasi R; Sarna T; Swartz HM Neuroscience; 1996 Jul; 73(2):407-15. PubMed ID: 8783258 [TBL] [Abstract][Full Text] [Related]
18. Selectivity of melaninized nigra-striatal dopamine neurons to degeneration in Parkinson's disease may depend on iron-melanin interaction. Ben-Shachar D; Youdim MB J Neural Transm Suppl; 1990; 29():251-8. PubMed ID: 2193109 [TBL] [Abstract][Full Text] [Related]
19. New face of neuromelanin. Double KL; Halliday GM J Neural Transm Suppl; 2006; (70):119-23. PubMed ID: 17017518 [TBL] [Abstract][Full Text] [Related]
20. Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content? Kastner A; Hirsch EC; Lejeune O; Javoy-Agid F; Rascol O; Agid Y J Neurochem; 1992 Sep; 59(3):1080-9. PubMed ID: 1494900 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]